|
NINL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.53133061786548E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
5.875600E-01 |
| Stage1-vs-Stage3 |
1.598200E-01 |
| Stage1-vs-Stage4 |
1.779070E-04 |
| Stage2-vs-Stage3 |
6.632200E-01 |
| Stage2-vs-Stage4 |
3.546200E-02 |
| Stage3-vs-Stage4 |
3.342300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.62680000026505E-07 |
| Normal-vs-Asian |
1.86528570367273E-12 |
| Caucasian-vs-AfricanAmerican |
6.794600E-01 |
| Caucasian-vs-Asian |
9.192800E-01 |
| AfricanAmerican-vs-Asian |
8.007400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.21565038222616E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.169600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(81-100Yrs) |
5.0914000004898E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.553600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.511000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.273800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.596000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.171200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.355200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.381100E-03 |
| Classical-VS-Follicular |
4.356300E-02 |
| Classical-VS-Other |
3.209800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
2.481400E-01 |
| Tall-VS-Other |
1.208610E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
1.312430E-01 |
| Follicular-VS-Normal |
1.62447832963153E-12 |
| Other-VS-Normal |
7.376200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
1.456250E-01 |
|
|
